Zena Wilson

发表

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

A. Rabow, D. M. Andrews, G. Walker, 2015, Journal of medicinal chemistry.

An innovative non-invasive technique for subcutaneous tumour measurements

Zena Wilson, Marcin Paczkowski, Anna Chabokdast, 2019, bioRxiv.

pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry

Jeffrey R. Whiteaker, A. Paulovich, J. Barrett, 2018, British Journal of Cancer.

Running title : Pharmacology of SERD inhibitor in breast cancer models

Graham, A. Rabow, R. A. Norman, 2016 .

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

O. Delpuech, J. Armenia, M. O’Connor, 2022, Oncoimmunology.

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib

A. Lau, M. O’Connor, R. Odedra, 2022, Cancer research.

Discovery of a Thiadiazole-Pyridazine Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.

Mairi M. Littleson, Peter D Smith, Peng-Fei Wang, 2019, Journal of medicinal chemistry.

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

A. Lau, Zena Wilson, A. Ramos-Montoya, 2020, Oncogene.

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

A. Biankin, S. Barry, D. Chang, 2016, Cancer cell.

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

G. Mills, C. Caldas, J. Barrett, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

Zena Wilson, M. Shibuya, S. Barry, 2011, Molecular Cancer Therapeutics.

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.

J. Nissink, A. Lau, P. Jewsbury, 2018, Journal of medicinal chemistry.

pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry

Jeffrey R. Whiteaker, A. Paulovich, J. Barrett, 2018, British Journal of Cancer.

Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress.

J. Bartek, A. Lau, M. O’Connor, 2019, Cancer research.

Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.

J. Waterton, A. Ryan, S. Ashton, 2007, Neoplasia.

Identifying strategies to target the metabolic flexibility of tumours

Xin Chen, N. Hay, P. Driscoll, 2020, Nature Metabolism.

PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary

S. Barry, S. Ashton, S. Wedge, 2016, Toxicologic pathology.

CXCR 2 Inhibition Profoun dly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma Graphical Abstract Highlights

A. Biankin, S. Barry, D. Chang, 2016 .

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

A. Rabow, G. Walker, R. A. Norman, 2016, Cancer research.

Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)

A. Rabow, D. M. Andrews, G. Walker, 2015 .

Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models

A. Lau, Zena Wilson, E. Cadogan, 2023, Cancers.

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

M. Cobbold, F. Calero-Nieto, Zena Wilson, 2024, Nature communications.

Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress.

J. Bartek, A. Lau, M. O’Connor, 2019, Cancer research.